289 related articles for article (PubMed ID: 21339222)
41. Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.
Zhang H; Chambers W; Sciascia S; Cuadrado MJ
Expert Rev Clin Pharmacol; 2016; 9(5):681-94. PubMed ID: 26907827
[TBL] [Abstract][Full Text] [Related]
42. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.
Wallace DJ; Navarra S; Petri MA; Gallacher A; Thomas M; Furie R; Levy RA; van Vollenhoven RF; Cooper S; Zhong ZJ; Freimuth W; Cervera R;
Lupus; 2013 Feb; 22(2):144-54. PubMed ID: 23213069
[TBL] [Abstract][Full Text] [Related]
43. T-cell-directed therapies in systemic lupus erythematosus.
Nandkumar P; Furie R
Lupus; 2016 Sep; 25(10):1080-5. PubMed ID: 27497252
[TBL] [Abstract][Full Text] [Related]
44. Update on the treatment of systemic lupus erythematosus: therapeutic highlights from the Sixth International Lupus Conference.
Abu-Shakra M; Buskila D
Isr Med Assoc J; 2002 Jan; 4(1):71-3. PubMed ID: 11802320
[TBL] [Abstract][Full Text] [Related]
45. Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus.
Chang HK
J Korean Med Sci; 2005 Oct; 20(5):883-5. PubMed ID: 16224167
[TBL] [Abstract][Full Text] [Related]
46. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus.
McMurray RW; Elbourne KB; Lagoo A; Lal S
J Rheumatol; 1998 Dec; 25(12):2364-70. PubMed ID: 9858431
[TBL] [Abstract][Full Text] [Related]
47. Mycophenolate mofetil: a magic bullet for lupus?
McCune WJ; Riskalla MM
J Rheumatol; 2005 Jun; 32(6):967-70. PubMed ID: 15940751
[No Abstract] [Full Text] [Related]
48. Targeted therapies in systemic lupus erythematosus.
Grech P; Khamashta M
Lupus; 2013 Sep; 22(10):978-86. PubMed ID: 23963429
[TBL] [Abstract][Full Text] [Related]
49. Anifrolumab (Saphnelo) for systemic lupus erythematosus.
Med Lett Drugs Ther; 2021 Sep; 63(1633):146-147. PubMed ID: 34550961
[No Abstract] [Full Text] [Related]
50. Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.
Al Rayes H; Touma Z
Drug Des Devel Ther; 2014; 8():2303-10. PubMed ID: 25429203
[TBL] [Abstract][Full Text] [Related]
51. New therapeutic avenues in SLE.
Bakshi J; Ismajli M; Rahman A
Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):794-809. PubMed ID: 27107514
[TBL] [Abstract][Full Text] [Related]
52. Belimumab: a guide to its use in systemic lupus erythematosus.
Scott LJ; Burness CB; McCormack PL
BioDrugs; 2012 Jun; 26(3):195-9. PubMed ID: 22428610
[TBL] [Abstract][Full Text] [Related]
53. Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis.
Kazderova M; Jancova E; Rysava R; Merta M; Tesar V
Arch Med Res; 2008 Jan; 39(1):115-9. PubMed ID: 18068004
[TBL] [Abstract][Full Text] [Related]
54. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil.
Zahr N; Arnaud L; Marquet P; Haroche J; Costedoat-Chalumeau N; Hulot JS; Funck-Brentano C; Piette JC; Amoura Z
Arthritis Rheum; 2010 Jul; 62(7):2047-54. PubMed ID: 20506558
[TBL] [Abstract][Full Text] [Related]
55. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?
Kalunian KC
Lupus; 2016 Sep; 25(10):1097-101. PubMed ID: 27497254
[TBL] [Abstract][Full Text] [Related]
56. Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature.
Prete M; Fatone MC; Vacca A; Racanelli V; Perosa F
Clin Exp Rheumatol; 2014; 32(2):267-74. PubMed ID: 24351505
[TBL] [Abstract][Full Text] [Related]
57. Belimumab therapy in systemic lupus erythematosus.
Zouali M; Uy EA
BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
[TBL] [Abstract][Full Text] [Related]
58. Hypersensitivity to mycophenolate mofetil in systemic lupus erythematosus: diagnostic measures and successful desensitization.
Szyper-Kravitz M; Sheinberg P; Sidi Y; Schiffenbauer Y; Trubniykov E; Shoenfeld Y
Int Arch Allergy Immunol; 2005 Dec; 138(4):334-6. PubMed ID: 16224194
[TBL] [Abstract][Full Text] [Related]
59. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
Fassbinder T; Saunders U; Mickholz E; Jung E; Becker H; Schlüter B; Jacobi AM
Arthritis Res Ther; 2015 Apr; 17(1):92. PubMed ID: 25890338
[TBL] [Abstract][Full Text] [Related]
60. Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus.
Fanouriakis A; Boumpas DT; Bertsias GK
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):437-51. PubMed ID: 22114854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
